For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | |
|---|---|---|---|---|
| Total revenues | 0 | 640* | 875 | |
| Research and development | 730 | 383* | 348 | |
| General and administrative | 2,479 | 1,535* | 1,533 | |
| Total cost and expenses | 3,209 | 1,918* | 1,881 | |
| Loss from operations | -3,209 | -1,278* | -1,006 | |
| Interest income | 32 | 38* | 30 | |
| Gain from settlement of account payable | - | 0* | 0 | |
| Gain from insurance recovery | - | 1,363* | 0 | |
| Total other income, net | 32 | 1,401* | 30 | |
| Net loss | - | 122* | -976 | |
| Foreign currency translation adjustment loss | - | 0* | 0 | |
| Comprehensive loss | - | 122 | -976 | |
| Net loss and other comprehensive loss | -3,177 | - | - | |
| Basic EPS | -0.76 | 0.032 | -0.3 | |
| Diluted EPS | -0.76 | 0.032 | -0.3 | |
| Basic Average Shares | 4,205,000 | 3,762,000 | 3,225,000 | |
| Diluted Average Shares | 4,205,000 | 3,762,000 | 3,225,000 | |
Cyclerion Therapeutics, Inc. (CYCN)
Cyclerion Therapeutics, Inc. (CYCN)